HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Donald Banerji Selected Research

indacaterol-glycopyrronium combination

11/2015FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.
1/2015LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
1/2015QVA149 Improves Lung Function, Dyspnea, and Health Status Independent of Previously Prescribed Medications and COPD Severity: A Subgroup Analysis from the SHINE and ILLUMINATE Studies.
1/2015Symptoms and impact of COPD assessed by an electronic diary in patients with moderate-to-severe COPD: psychometric results from the SHINE study.
10/2014Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients.
6/2014Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study.
6/2014Recent advances in COPD disease management with fixed-dose long-acting combination therapies.
4/2014Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
12/2013Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study.
10/2013Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Donald Banerji Research Topics

Disease

43Chronic Obstructive Pulmonary Disease (COPD)
04/2020 - 06/2011
5Dyspnea (Shortness of Breath)
08/2017 - 01/2012
5Obstructive Lung Diseases (Obstructive Lung Disease)
01/2017 - 06/2011
4Pneumonia (Pneumonitis)
01/2017 - 10/2014
4Asthma (Bronchial Asthma)
01/2008 - 09/2005
2Allergic Rhinitis
05/2006 - 01/2003
1Eosinophilia
11/2017
1Cough
01/2015
1Atrial Flutter (Flutter, Atrial)
10/2014
1Perennial Allergic Rhinitis
05/2006
1Inflammation (Inflammations)
09/2005

Drug/Important Bio-Agent (IBA)

34Glycopyrrolate (Glycopyrronium Bromide)FDA LinkGeneric
01/2019 - 06/2011
29indacaterolIBA
01/2019 - 01/2012
18Muscarinic AntagonistsIBA
01/2018 - 06/2011
17Bronchodilator Agents (Bronchodilators)IBA
01/2018 - 06/2011
15Fluticasone (Cutivate)FDA LinkGeneric
01/2018 - 01/2003
14indacaterol-glycopyrronium combinationIBA
11/2015 - 01/2013
13Salmeterol Xinafoate (Serevent)FDA Link
01/2018 - 03/2013
12Tiotropium Bromide (Spiriva)FDA Link
01/2018 - 06/2011
12Adrenal Cortex Hormones (Corticosteroids)IBA
01/2018 - 09/2005
5GoldIBA
01/2016 - 01/2013
4ciclesonideFDA Link
01/2008 - 09/2005
3Fluticasone-Salmeterol Drug Combination (Advair)FDA Link
01/2019 - 01/2016
3vilanterolIBA
12/2017 - 06/2014
3GSK573719IBA
12/2017 - 06/2014
2SteroidsIBA
05/2006 - 09/2005
2Triamcinolone Acetonide (Azmacort)FDA LinkGeneric
05/2006 - 01/2003
1Indicators and Reagents (Reagents)IBA
01/2018
1maleic acid (maleate)IBA
12/2017
1BromidesIBA
12/2017
1Biomarkers (Surrogate Marker)IBA
01/2017
1GlucocorticoidsIBA
01/2016
1Pharmaceutical PreparationsIBA
01/2016
1omega-Chloroacetophenone (Mace)IBA
10/2014
1fluticasone furoateFDA Link
06/2014
1PowdersIBA
12/2011
1Nasal SpraysIBA
05/2006
1norflurane (R 134a)IBA
05/2006
1Prednisone (Sone)FDA LinkGeneric
05/2006
1Albuterol (Salbutamol)FDA LinkGeneric
12/2005

Therapy/Procedure

10Therapeutics
04/2020 - 12/2005
1Nebulizers and Vaporizers (Inhaler)
01/2018